¸¸¼º ôÃß¿°ÁõÀ» Ư¡ÀÎ °Á÷ôÃß¿° Àü¹®°¡
·ù¸¶Æ¼½º ÁúȯÁß ÃµÀå°üÀýÀÇ ¿°ÁõÀ» ½ÃÀÛÀ¸·Î ¸¸¼ºÀûÀΠôÃß °Á÷À» ÀÏÀ¸Å°´Â °Á÷ôÃß¿°ÀÇ Àü¹®°¡·Î ÇöÀç±îÁö 30¿©³â °Á÷ôÃß¿°, ôÃß°üÀý¿° Áø·áÇÔ. ±¹³» ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ¿¬±¸ »Ó ¾Æ´Ï¶ó ±¹Á¦ Àü¹®°¡¿Í ÇÔ²² °Á÷ôÃß¿°ÀÇ À¯Àü, º´ÀDZâÀü ¹× Ä¡·á¿¡ ´ëÇÑ ´Ù¼öÀÇ ¿¬±¸ °æÇèÀÌ ÀÖ½¿
Á¦ ¸ñ | Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2020 | ¹ßÇ¥Áö | Ann Rheum Dis |
Á¦ ¸ñ | Clinical and genetic factors associated with radiographic damage in patients with ankylosing spondylitis | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | Ann Rheum Dis |
Á¦ ¸ñ | Prevalence of comorbidities and evaluation of their screening in spondyloarthritis | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2016 | ¹ßÇ¥Áö | Ann Rheum Dis |
Á¦ ¸ñ | The presence of peripheral arthritis delays spinal radiographic progression in ankylosing spondylitis | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2014 | ¹ßÇ¥Áö | rheumatology |
Á¦ ¸ñ | Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1) | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2019 | ¹ßÇ¥Áö | Lancet |
Á¦ ¸ñ | Ixekizumab Treatment in Patients with Non-Radiographic Axial Spondyloarthritis | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2020 | ¹ßÇ¥Áö | Lancet |
Á¦ ¸ñ | Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2) | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2022 | ¹ßÇ¥Áö | Lancet |
°Á÷ôÃß¿°ÀÇ ÀÓ»ó ¹× Ä¡·á, °Á÷ôÃß¿° ¹× ôÃß°üÀý¿°ÀÇ º´ÀÎ ¿¬±¸
±×µ¿¾È ¿¬±¸ ¹× °æÇèÀ» ±â¹ÝÀ¸·Î ȯÀÚ¸¦ Ä¡·áÇϰí ÀÖ½À´Ï´Ù. ²ÙÁØÇÑ Ä¡·á¿Í Ä¡·áµÉ ¼ö ÀÖ´Ù´Â ÀڽۨÀÌ ÀÖÀ¸¸é ¸¸¼ºÁúȯÀ» ±Øº¹ ÇÒ ¼ö ÀÖ½À´Ï´Ù.
°Á÷ôÃß¿°À» Æ÷ÇÔÇÑ ·ù¸¶Æ¼½ºÁúȯÀÌ ¸¸¼ºÁúȯÀ̶ó ÁÁ¾ÆÁú ¼ö ÀÖ´Ù´Â ¹ÏÀ½°ú ²ÙÁØÇÑ Ä¡·á°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀÇ»ç¿Í ȯÀÚ ¸ðµÎ ³ë·ÂÇÏ¸é ¾î·Á¿òÀ» ±Øº¹ ÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÇѾç´ëÇб³º´¿øÀº 1972³â °³¿ø ÀÌÈÄ, »ç¶ûÀÇ ½Çõ Á¤½ÅÀ» ¹ÙÅÁÀ¸·Î ÀÇ·áÀÇ ÇѰ迡 µµÀüÇϸç, Çõ½ÅÀûÀÎ ¼º°ú¸¦ ÀÌ·ï¿Ô½À´Ï´Ù. ·ù¸¶Æ¼½º ¹× ½Å°æ°èÁúȯ Ä¡·áÀÇ ¼±µµ º´¿ø°ú ÁßÁõ ¾ÏÁúȯ µî¿¡ ÃֽеðÁöÅÐ Çõ½Å ±â¼ú°ú ¿¬±¸Á߽ɺ´¿øÀ¸·Î¼ AI, ºòµ¥ÀÌÅÍ µîÀ» Ȱ¿ëÇÑ ÀÓ»ó ¿¬±¸¸¦ °ÈÇÏ¸ç ¹Ì·¡ ÀÇÇÐÀ» À̲ø°í ÀÖ½À´Ï´Ù.
¼¿ïƯº°½Ã ¼ºµ¿±¸ ¿Õ½Ê¸®·Î 222-1